- Home
- NRO vs STTK Comparison
NRO vs STTK Comparison
Compare NRO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- STTK
- Stock Information
- Founded
- NRO 2003
- STTK 2016
- Country
- NRO United States
- STTK United States
- Employees
- NRO N/A
- STTK N/A
- Industry
- NRO Finance/Investors Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- STTK Health Care
- Exchange
- NRO Nasdaq
- STTK Nasdaq
- Market Cap
- NRO 187.8M
- STTK 56.8M
- IPO Year
- NRO N/A
- STTK 2020
- Fundamental
- Price
- NRO $3.50
- STTK $1.12
- Analyst Decision
- NRO
- STTK Hold
- Analyst Count
- NRO 0
- STTK 3
- Target Price
- NRO N/A
- STTK $2.00
- AVG Volume (30 Days)
- NRO 239.4K
- STTK 182.2K
- Earning Date
- NRO 01-01-0001
- STTK 02-27-2025
- Dividend Yield
- NRO 11.41%
- STTK N/A
- EPS Growth
- NRO N/A
- STTK N/A
- EPS
- NRO N/A
- STTK N/A
- Revenue
- NRO N/A
- STTK $6,435,000.00
- Revenue This Year
- NRO N/A
- STTK $313.04
- Revenue Next Year
- NRO N/A
- STTK N/A
- P/E Ratio
- NRO N/A
- STTK N/A
- Revenue Growth
- NRO N/A
- STTK 382.75
- 52 Week Low
- NRO $2.51
- STTK $0.94
- 52 Week High
- NRO $3.45
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- NRO 42.49
- STTK 43.75
- Support Level
- NRO $3.52
- STTK $1.13
- Resistance Level
- NRO $3.62
- STTK $1.39
- Average True Range (ATR)
- NRO 0.08
- STTK 0.11
- MACD
- NRO 0.01
- STTK 0.00
- Stochastic Oscillator
- NRO 40.00
- STTK 18.18
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.